This 2012 pooled analysis of 41 clinical trials assessed weight changes in 3,187 patients treated with pregabalin (150–600 mg/day) over one year. The majority (81.8%) maintained weight within ±7% of baseline. However, 14.5% were “delayed weight gainers,” exceeding 7% weight gain after two months, and 2.6% were “early weight gainers,”
This 1998 review by Timothy C. Birdsall, N.D., explores the clinical efficacy of 5-hydroxytryptophan (5-HTP) as a serotonin precursor. 5-HTP, derived from L-tryptophan or extracted from Griffonia simplicifolia seeds, bypasses the rate-limiting step of serotonin synthesis and crosses the blood-brain barrier without a transport molecule. It is well absorbed orally,
This 2002 review by Dr. Alan R. Gaby discusses the clinical application of the “Myers’ cocktail,” an intravenous vitamin and mineral formula originally developed by Dr. John Myers. The modified cocktail typically includes magnesium, calcium, B vitamins, and vitamin C. Over an 11-year period, approximately 15,000 injections were administered to
This 2013 study by Stejskal et al. investigated the prevalence and clinical relevance of metal allergies in 15 female fibromyalgia (FM) patients. Using the MELISA® lymphocyte transformation test, all patients exhibited sensitivity to at least one metal, with nickel, inorganic mercury, cadmium, and lead being the most common allergens. Following
This systematic review and meta-analysis evaluated the safety profile of oral naltrexone by analyzing serious adverse events (SAEs) reported in placebo-controlled randomized controlled trials (RCTs). A total of 89 RCTs involving 11,194 participants across various conditions—including alcohol use disorders, psychiatric disorders, impulse control disorders, obesity, Crohn’s disease, fibromyalgia, and cancer—were
This 2018 review explores the pharmacological properties and therapeutic applications of low-dose naltrexone (LDN), defined as daily doses between 1 and 5 mg. LDN modulates the immune system by transiently blocking opioid receptors, leading to upregulation of endogenous opioids and reduction of pro-inflammatory cytokines via Toll-like receptor 4 (TLR4) antagonism.
This 2008 clinical study evaluated the effects of Waon therapy—a form of far-infrared dry sauna treatment—on 13 female patients with fibromyalgia syndrome (FMS). Patients underwent 60°C sauna sessions for 15 minutes, followed by 30 minutes of rest in a 26–27°C room while covered with a blanket. Pain reductions were observed
This review explores the role of the kynurenine pathway in the pathophysiology of CFS and FM, highlighting how its dysregulation, often due to chronic inflammation, leads to tryptophan depletion and neuroimmune disturbances. The author suggests that deficiencies in nicotinamide and other cofactors, resulting from an overactive kynurenine pathway, may exacerbate
This study evaluated the efficacy of oxygen-ozone autohemotherapy (O2-O3-AHT) for treating fibromyalgia (FM), a chronic condition characterized by pain, fatigue, and musculoskeletal issues. Involving 200 patients, the study demonstrated that 76% of participants experienced significant rehabilitation of musculoskeletal function and reduced arthralgia after 3-4 O2-O3-AHT sessions. Pain scores measured using
This 2013 open-label pilot study titled “Ozone therapy as add-on treatment in fibromyalgia management by rectal insufflation” (Journal of Alternative and Complementary Medicine, DOI: [10.1089/acm.2011.0739]*) evaluated the effects of ozone therapy administered via rectal insufflation over 12 weeks in fibromyalgia patients. Participants showed significant improvements in Fibromyalgia Impact Questionnaire (FIQ)
